

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Pavliv Leo</u>  (Last) (First) (Middle) 2525 WEST END AVE. SUITE 950  (Street) NASHVILLE TN 37203  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/10/2009	3. Issuer Name and Ticker or Trading Symbol <u>CUMBERLAND PHARMACEUTICALS INC [ CPX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Vice President, Operations	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	-------------------------------------------------------	----------------------------------------------------------	-------------------------------------------------------

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Options	12/27/1999	12/27/2009	Common Stock	5,000	0.5	D	
Options	05/15/2000	05/15/2010	Common Stock	18,000	0.93	D	
Options	09/30/2001	09/30/2011	Common Stock	3,000	1.63	D	
Options	12/31/2003	04/14/2013	Common Stock	40,000	3.5	D	
Options	12/31/2004	04/14/2013	Common Stock	40,000	3.5	D	
Options	12/31/2005	04/14/2013	Common Stock	40,000	3.5	D	
Options	12/31/2006	04/14/2013	Common Stock	40,000	3.5	D	
Options	12/31/2007	02/02/2017	Common Stock	3,000	11	D	
Options	12/31/2008	02/02/2017	Common Stock	3,000	11	D	
Options	12/31/2008	07/22/2018	Common Stock	2,250	13	D	
Options	12/31/2009	01/15/2015	Common Stock	40,000	6	D	
Options	12/31/2009	02/02/2017	Common Stock	3,000	11	D	
Options	12/31/2009	02/16/2019	Common Stock	2,250	13	D	
Options	12/31/2009	07/22/2018	Common Stock	2,250	13	D	
Options	12/31/2010	02/02/2017	Common Stock	3,000	11	D	
Options	12/31/2010	02/16/2019	Common Stock	2,500	13	D	
Options	12/31/2010	07/22/2018	Common Stock	2,250	13	D	
Options	12/31/2011	02/16/2019	Common Stock	2,500	13	D	
Options	12/31/2011	07/22/2018	Common Stock	2,250	13	D	
Options	12/31/2012	02/16/2019	Common Stock	2,500	13	D	

Explanation of Responses:

Remarks:

Leo Pavliv by: /s/ Jean W. Marstiller, as Attorney-in-fact 08/10/2009

\*\* Signature of Reporting Person Date

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

